Infliximab for the treatment of rheumatoid arthritis.
BACKGROUND: Infliximab is a human murine chimeric anti-tumour necrosis factor alpha monoclonal antibody recently approved for the treatment of refractory RA. OBJECTIVES: To assess the efficacy and safety of infliximab for the treatment of rheumatoid arthritis. SEARCH STRATEGY: Electronic databases...
Autori principali: | , , , , , , |
---|---|
Natura: | Journal article |
Lingua: | English |
Pubblicazione: |
2002
|